Stevioside modulates oxidative damage in the liver and kidney of high fat/low streptozocin diabetic rats

Heliyon

Volumn 4, Issue 5, 2018, Pages

  Rotimi, Solomon Oladapo ^a   Rotimi, Oluwakemi Anuoluwapo ^a   Adelani, Isaacson Bababode ^a   Onuzulu, Chinonye ^a   Obi, Patience ^a   Okungbaye, Rotimi ^a  

^a Centre for Economic Policy and Development Research   (Nigeria)

Author keywords

Metabolism; Nutrition

Indexed keywords

EID: 85047616312     PISSN: 24058440     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.heliyon.2018.e00640     Document Type: Article

References (56)

1. Carrera-Lanestosa, A., Moguel-Ordonez, Y., Segura-Campos, M., Stevia rebaudiana Bertoni: a natural alternative for treating diseases associated with metabolic syndrome. J. Med. Food 20:10 (2017), 933–943.
2. Fiorentino, T.V., et al. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr. Pharm. Des. 19:32 (2013), 5695–5703.
3. Grindel, A., et al. Oxidative stress, DNA damage and DNA repair in female patients with diabetes mellitus type 2. PLoS One, 11(9), 2016, e0162082.
4. Rippe, J.M., Angelopoulos, T.J., Relationship between added sugars consumption and chronic disease risk factors: current understanding. Nutrients, 8(11), 2016, 697.
5. Rippe, J.M., Angelopoulos, T.J., Added sugars and risk factors for obesity, diabetes and heart disease. Int. J. Obes. (Lond) 40:Suppl 1 (2016), S22–S27.
6. Reed, D.R., McDaniel, A.H., The human sweet tooth. BMC Oral Health, 6(Suppl 1), 2006, S17.
7. Crammer, B., Sweet glycosides from the stevia plant. Chem. Br. 22 (1986), 915–918.
8. J.F.W.E.C.o.F.A. Meeting, W.H. Organization, Safety Evaluation of Certain Food Additives. 2006, World Health Organization.
9. Koyama, E., et al. Absorption and metabolism of glycosidic sweeteners of stevia mixture and their aglycone, steviol, in rats and humans. Food Chem. Toxicol. 41:6 (2003), 875–883.
10. Hsieh, M.H., et al. Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: a two-year, randomized, placebo-controlled study. Clin. Ther. 25:11 (2003), 2797–2808.
11. Prata, C., et al. Glycosides from Stevia rebaudiana Bertoni possess insulin-mimetic and antioxidant activities in rat cardiac fibroblasts. Oxidative Med. Cell. Longev., 2017, 2017, 3724545.
12. Bender, C., Graziano, S., Zimmermann, B.F., Study of Stevia rebaudiana Bertoni antioxidant activities and cellular properties. Int. J. Food Sci. Nutr. 66:5 (2015), 553–558.
13. A. Roberts, I. Munro, Stevioside and related compounds: therapeutic benefits beyond sweetness, Pharmacol. Ther. 122 (3) (2009) e1–e2.
14. Ilic, V., et al. Insight into anti-diabetic effect of low dose of stevioside. Biomed. Pharmacother. 90 (2017), 216–221.
15. Skovso, S., Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J. Diabetes Investig. 5:4 (2014), 349–358.
16. Rotimi, S.O., et al. Naringin enhances reverse cholesterol transport in high fat/low streptozocin induced diabetic rats. Biomed. Pharmacother. 101 (2018), 430–437.
17. Zhang, M., et al. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp. Diabetes Res., 2008, 2008, 704045.
18. Rotimi, S.O., et al. Tissue dyslipidemia in Salmonella-infected rats treated with amoxillin and pefloxacin. Lipids Health Dis., 11, 2012, 152.
19. Rotimi, S.O., et al. Amoxillin- and pefloxacin-induced cholesterogenesis and phospholipidosis in rat tissues. Lipids Health Dis., 14, 2015, 13.
20. Cushman, D.W., Cheung, H.S., Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem. Pharmacol. 20:7 (1971), 1637–1648.
21. Rifai, N., Warnick, G.R., Dominiczak, M.H., Handbook of Lipoprotein Testing. 2000, Amer. Assoc. for Clinical Chemistry.
22. Buege, J.A., Aust, S.D., [30] Microsomal Lipid Peroxidation, Methods in Enzymology. 1978, Elsevier, 302–310.
23. Ellman, G.L., Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:1 (1959), 70–77.
24. Habig, W.H., Pabst, M.J., Jakoby, W.B., Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249:22 (1974), 7130–7139.
25. Rotruck, J.T., et al. Selenium: biochemical role as a component of glutathione peroxidase. Science 179:4073 (1973), 588–590.
26. Mavis, R.D., Stellwagen, E., Purification and subunit structure of glutathione reductase from bakers’ yeast. J. Biol. Chem. 243:4 (1968), 809–814.
27. Marklund, S., Marklund, G., Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 47:3 (1974), 469–474.
28. Fergusson, R.R., Chance, B., Substrate specificity of peroxidase. Science 122:3167 (1955), 466–467.
29. Rotimi, S.O., et al. Hesperidin prevents lipopolysaccharide-induced endotoxicity in rats. Immunopharmacol. Immunotoxicol. 38:5 (2016), 364–371.
30. Lowry, O.H., et al. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1 (1951), 265–275.
31. Suman, S., Pandey, A., Chandna, S., An improved non-enzymatic “DNA ladder assay” for more sensitive and early detection of apoptosis. Cytotechnology 64:1 (2012), 9–14.
32. Filimonov, D., et al. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem. Heterocycl. Comp. 50:3 (2014), 444–457.
33. Barriocanal, L.A., et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in Type 1 and Type 2 diabetics. Regul. Toxicol. Pharmacol. 51:1 (2008), 37–41.
34. Latha, S., Chaudhary, S., Ray, R.S., Hydroalcoholic extract of Stevia rebaudiana bert. leaves and stevioside ameliorates lipopolysaccharide induced acute liver injury in rats. Biomed. Pharmacother. 95 (2017), 1040–1050.
35. Gall, W.E., et al. α-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One, 5(5), 2010, e10883.
36. Wilding, J.P., The importance of free fatty acids in the development of Type 2 diabetes. Diabet. Med. 24:9 (2007), 934–945.
37. Boden, G., Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 111:3 (2003), 121–124.
38. Green, B.D., Flatt, P.R., Bailey, C.J., Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc. Dis. Res. 3:3 (2006), 159–165.
39. Augustyns, K., et al. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. 12:8 (2005), 971–998.
40. Rotimi, S.O., Omotosho, O.E., Rotimi, O.A., Persistence of acidosis in alloxan-induced diabetic rats treated with the juice of Asystasia gangetica leaves. Pharmacogn. Mag. 7:25 (2011), 25–30.
41. Newman, J.C., Verdin, E., β-hydroxybutyrate: much more than a metabolite. Diabetes Res. Clin. Pract. 106:2 (2014), 173–181.
42. Garcia-Guerra, L., et al. G protein–coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes 59:10 (2010), 2407–2417.
43. Vila-Bedmar, R., et al. Reversal of diet-induced obesity and insulin resistance by inducible genetic ablation of GRK2. Sci. Signal., 8(386), 2015, ra73.
44. Melis, M.S., Stevioside effect on renal function of normal and hypertensive rats. J. Ethnopharmacol. 36:3 (1992), 213–217.
45. Toskulkac, C., et al. Acute toxicity of stevioside, a natural sweetener, and its metabolite, steviol, in several animal species. Drug Chem. Toxicol. 20:1-2 (1997), 31–44.
46. Rotimi, S.O., et al. Inability of legumes to reverse diabetic-induced nephropathy in rats despite improvement in blood glucose and antioxidant status. J. Med. Food 13:1 (2010), 163–169.
47. Bernstein, K.E., et al. Renal angiotensin-converting enzyme and blood pressure control. Curr. Opin. Nephrol. Hypertens., 23(2), 2014, 106.
48. Marshall, S., Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus. Diabet. Med. 16:5 (1999), 358–372.
49. Komers, R., Komersova, K., Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes. Expert Opin. Investig. Drugs 9:11 (2000), 2601–2617.
50. Hsu, Y.H., et al. Antihypertensive effect of stevioside in different strains of hypertensive rats. Zhonghua Yi Xue Za Zhi (Taipei) 65:1 (2002), 1–6.
51. Ferri, L.A., et al. Investigation of the antihypertensive effect of oral crude stevioside in patients with mild essential hypertension. Phytother. Res. 20:9 (2006), 732–736.
52. Chan, P., et al. A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. Br. J. Clin. Pharmacol. 50:3 (2000), 215–220.
53. Taylor, R., Insulin resistance and type 2 diabetes. Diabetes 61:4 (2012), 778–779.
54. Belmonte, S.L., Blaxall, B.C., G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ. Res. 109:3 (2011), 309–319.
55. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ. Res. 107:9 (2010), 1058–1070.
56. Kawahito, S., Kitahata, H., Oshita, S., Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J. Gastroenterol., 15(33), 2009, 4137.